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Abstract
Aims and Methods: We evaluated the modulation of liver stearoyl-CoA desaturase-1 (Scd1) by dietary factors and
insulin resistance (IR) in two experimental models of high-fat diet (HFD)-induced nonalcoholic fatty liver disease
(NAFLD). The first model included Sprague Dawley (SD) rats that developed NAFLD without IR, and the second one
included a rat model of genetic IR and cardiovascular disease, the spontaneously hypertensive rats (SHR) and its
normotensive, insulin-sensitive control Wistar-Kyoto (WKY). The adult rats were given standard chow diet (CD) or
HFD for 10 weeks. In all the animals, we explored the hepatic Scd1 transcriptional activity and protein levels.
Results: HFD-fed rats of both strains developed severe NAFLD. Liver abundance of Scd1 mRNA was significantly
decreased in HFD-fed rats regardless of the strain; SD-CD: 235±195 vs. SD-HFD 4.5±2.9, p<0.0004, and SHR-CD:
75.6±10.8 vs. SHR-HFD: 4.48±17.4, and WKY-CD: 168.7±17.4 vs. WKY-HFD: 12.9±17.4, p<0.000001 (mean±SE,
ANCOVA adjusted by HOMA). Analysis of liver Scd1 protein expression showed a particular pattern in the HFD
groups, characterized by the presence of high levels of a monomeric protein band (32.2–36.6 Kda, p<0.003) and
decreased levels of a dimeric protein band (61.9–66.1 Kda, p<0.02) regardless of the rat strain. Pharmacologic
intervention with the peroxisome proliferator-activated receptor α agonist clofibrate reverted the liver phenotype and
significantly modified the hepatic Scd1 transcriptional activity and protein expression.
Conclusion: Diet-induced fatty liver is associated with the downregulation of hepatic Scd1 transcript and de-
dimerization of the protein, and these changes were not much affected by the status of peripheral IR.
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Introduction
Stearoyl-CoA desaturase (SCD), also known as fatty acid
desaturase or delta (9)-desaturase, is a microsomal enzyme
involved in the biosynthesis of monounsaturated fatty acids
(MUFAs), primarily oleate (C18:1) and palmitoleate (C16:1).
Therefore, SCD is a key enzyme in the regulation of the lipid
metabolism and synthesis of triacylglycerols; SCD1 is
differentially expressed in the liver.
Evidence from experimental and human studies has shown
that SCD1 participates in the modulation of metabolic
syndrome (MS)-associated phenotypes [1], including obesity
[2], insulin resistance (IR) [3,4], and nonalcoholic fatty liver
disease (NAFLD) [5,6], and it has been suggested that Scd1 is
required for the onset of diet-induced hepatic IR in rodents [4].
Although SCD1 is a central lipogenic enzyme, its specific
role in the development of human metabolic diseases is
controversial. For example, previous in vitro studies have
shown that SCD1 depletion leads to decreased synthesis of
PLOS ONE | www.plosone.org 1 September 2013 | Volume 8 | Issue 9 | e76912
MUFAs and phospholipids and promotes the accumulation of
saturated fatty acid-enriched unesterified fatty acids and
triacylglycerol [7]. In addition, Scd1 inhibition in mice promotes
atherosclerosis, reduces HDL cholesterol, and produces a
significant enrichment of saturated free fatty acids, and the
majority of these changes are originated in tissues involved in
lipid biosynthesis, such as the liver [8].
Conversely, studies in mice with targeted disruption of Scd1
have suggested that the enzyme deficiency is associated with
an activation of lipid oxidation in addition to reduced triglyceride
synthesis and storage [9].
As previously mentioned, the metabolism of free fatty acids
takes place primarily in the liver. Thus, the understanding of the
behavior of hepatic SCD1 under metabolic or dietary stress is
relevant to the understanding of the pathogenesis of the MS.
Unfortunately, the modulation of liver SCD1 transcriptional
activity in NAFLD is still unclear. In fact, whereas some
experimental studies have shown that hepatic Scd1 expression
increases during high-fat diet (HFD) [10,11], other studies have
indicated that the expression is significantly decreased [12]. An
elegant review that summarizes the mechanisms behind the
SCD1 activity and its relationship with metabolic disorders was
recently published [13].
Also, there is still inconsistent data about the regulation of
liver SCD1 expression in human NAFLD. For instance, some
clinical studies have shown that hepatic SCD1 activity
increases with increasing liver fat content [14], being a
determinant of liver fat accumulation under lipogenic dietary
conditions [15] or obesity [16]. On the contrary, others have
shown that SCD1 activity and mRNA expression are not
upregulated in subjects with fatty liver and that the hepatic
SCD1 activity index negatively correlates with hepatic fat
content [16].
Interestingly, much of these changes observed in SCD1
mRNA levels might be associated with the stability of the gene
transcript, which is strongly affected by the levels of
polyunsaturated fatty acids (PUFAs) [17,18]. In addition,
PUFAs are able to repress the expression of the Scd1 gene
[19,20].
Another interesting feature is that the stability of the SCD
proteins is much influenced by changes in the protein
oligomerization and dimerization, which play an important role
in regulating its half-life [21]. Indeed, the first reported that
suggested that protein oligomerization play a role in the
regulation of the stability of SCD enzymes was carried out in
the human SCD2 (hSCD2) protein, which encodes a 37.5-kDa
protein that shares 61% and 57% sequence identity with the
human SCD1 and murine SCD2 enzymes, respectively [21]. Of
note, both human SCD2 and rat SCD1 were proven to be
oligomeric proteins in intact cells by transfection
experiments[21].
Hence, to gain insights into the molecular events underlying
the association between Scd1, fatty liver, and IR, we explored
the hepatic expression of Scd1 in two experimental models of
HFD-induced NAFLD: Sprague Dawley (SD) rats with
increased visceral fat but without IR, and spontaneously
hypertensive and IR rats (SHR), a rat model of genetic MS and
cardiovascular disease (CVD), in comparison with its
normotensive, insulin-sensitive control Wistar-Kyoto (WKY)
strain. This strategy allowed us to explore the behavior of liver
Scd1 expression in different metabolic environments.
Materials and Methods
Ethics Statement
All experiments with animals were performed according to
the recommendations in the Guide for the Care and Use of
Laboratory Animals of the “Comite Institucional del Cuidado y
Uso de animals de Laboratorio (CICUAL) IDIM-UE” (Instituto
de Investigaciones Medicas-Unidad Ejecutora); the CICUAL
IDIM-UE approved this study. All animals received humane
care, according to the Guide for the Care and Use of
Laboratory Animals of Institute of Medical Research A Lanari-
IDIM, University of Buenos Aires-National Council of Scientific
and Technological Research (CONICET).
Animal models
HFD-induced NAFLD without IR.  Twelve-week-old male
SD rats weighing 280±20 g were purchased from the Research
Animal Facility of the School of Veterinary Medicine, University
of Buenos Aires. After acclimatization for 1 week, the rats were
randomly divided into two experimental groups. One group
included 10 rats that received standard chow diet (CD) for 10
weeks (control group). The other group, including 15 animals,
was allowed ad libitum access to HFD (40% w/w) consisting of
bovine and porcine fat added to CD, as previously described
[22], for the same period of time. The HFD provided 5340–
5460 Kcal/kg, 13.8% of proteins and 26.4% of carbohydrates
vs. 2900–3100 Kcal/kg, 23% of proteins and 44% of
carbohydrates for the CD.
Fatty acid composition of the HFD is as follows: saturated
free fatty acids: 42-43% (SFA=myristic (C14:0) + palmitic
(C16:0) + stearic (C18:0), monounsaturated: 30-37%
(MUFA=myristoleic (14:1) + palmitoleic (C16:1) + oleic (18:1),
n-6 polyunsaturated fatty acids: 5-7% (n-6 PUFA=linoleic
C18:2) + di-homo-gamma-linoleic C20:3 + arachidonic C20:4)
+ docosatetraenoic (C22:4) and n-3 PUFA 2-4% (linolenic
C18:3 + eicospentaenoic C20:5 + doc-osapentaenoic C22:5 +
docohexaenoic C22:6) (National Institute of Agricultural
Research, INTA, La Pampa, Argentina).
HFD-induced NAFLD in a genetically determined model
of IR and CVD.  Sixteen-week-old male SHR (n=13) and WKY
(n=14) rats (Charles River Laboratories, Wilmington, MA, USA)
were included in this experiment. After acclimatization for 1
week, rats of both strains were randomly divided into two
experimental groups. One group received CD for 10 weeks
(control group, SHR: n= 6 and WKY: n=7). The other group
was allowed ad libitum access to the same HFD described
above for 10 weeks (SHR: n=7 and WKY: n=7).
In all the animals, housed under controlled conditions of
temperature (23+1°C) and light (12-h light/dark cycle), food
intake and body weight were monitored daily. At the completion
of the study, food was withdrawn from 8:00 am to 4:00 pm
before the animals were anesthetized with pentobarbital, and
blood from individual rats was collected by cardiac puncture to
determine the plasma and serum levels of different parameters.
SCD1 and Fatty Liver
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Liver tissue was excised and weighed, and intraperitoneal and
retroperitoneal fat was weighted. The liver and fat weights were
expressed as liver/rat length (taken from the nose to the tail
origin) ratio (g/cm) to avoid the influence of body weight
change. The liver was snap-frozen and stored at −76°C until
gene expression analysis. A portion of each liver was fixed in
10% formalin for histologic analysis. Serum and sodium EDTA
plasma was obtained by centrifugation and stored at −80°C
until further use. Plasma insulin levels were determined with a
commercial quantitative ultra-sensitive ELISA rat kit according
to the manufacturer’s instruction (Crystal Chem Inc., Downers
Grove, IL, USA). IR was calculated by the homeostasis model
assessment (HOMA) index [fasting plasma insulin (µU/mL) ×
fasting plasma glucose (mmol/L)/22.5]. Leptin was measured
by ELISA (Leptin ELISA Development Kit, PeproTech Inc., NJ,
USA). All these measurements were done blinded to the
experimental groups. At the end of each experiment, rats were
sacrificed by intravenous administration of overdosed
pentobarbital.
Interventional experiment
Twelve-week-old male SD rats were given HFD for 8 weeks,
after which they were randomly divided into two groups. For 4
weeks, along with the same access to HFD, one group
received the agonist of the peroxisome proliferator-activated
receptor α (Pparα) clofibrate (n=5 rats, 75 mg/kg
intraperitoneally) every 24 h, and the other group (n=5 rats)
was fed with HFD; an additional control group (6 rats) was fed
with CD for 12 weeks. The animals were then killed, and liver
tissue samples were obtained to measure the Scd1 mRNA and
protein levels as previously described.
Measurement of liver triglyceride content
The liver triglyceride content was determined with an
automatic biochemical analytical system (Architect, Abbott,
Buenos Aires, Argentina), and the results were expressed as
micrograms of triglyceride per milligram of liver tissue (µg/mg
liver).
Histologic analysis of liver tissue.  With the use of light
microscopy, the steatosis and necroinflammation levels from
sections of formalin-fixed, paraffin-embedded samples stained
with H&E and Masson’s trichrome were assessed. The degree
of steatosis was assessed irrespective of the experimental
groups and graded from 0 to 4+ according to the percentage of
lipid-laden hepatocytes: 0, no steatosis; 1, fatty hepatocytes
occupying less than 10% of the parenchyma; 2, between 10
and 30%; 3, between 30 and 60%; and 4, fatty hepatocytes
occupying more than 60% of the parenchyma [23]. The severity
of necroinflammatory activity was expressed on a 3-point scale,
as follows: grade 1 (mild), grade 2 (moderate), and grade 3
(severe), as described by Brunt et al [23].
RNA preparation and real-time RT-PCR for quantitative
assessment of mRNA expression.  Total RNA was prepared
from rat livers through the phenol extraction step method, with
additional DNAse digestion. Total RNA was prepared from rat
livers using the phenol extraction step method, with an
additional DNAse digestion step. For RT-PCR, 3 µg of total
RNA was reverse-transcribed using random hexamers and
Moloney Murine Leukemia Virus (MMLV) reverse transcriptase
(Promega, Wis, USA). Real-time PCR was performed for
quantitative assessment of mRNA expression in an iCycler
thermocycler (BioRad, Hercules, CA) using the fluorescent dye
SYBR-Green (Invitrogen, Buenos Aires, Argentina). All the
real-time PCR reactions were run in duplicate, and all the
samples of the experimental groups were tested.
The relative abundance of the target gene mRNA was
normalized to the amount of a housekeeping gene (TATA box
binding protein, TBP) to carry out comparisons between the
groups. TBP was found to be the most stable reference gene
for testing liver mRNA expression among other housekeeping
genes tested before starting the experiment [β-actin,
peptidylprolyl isomerase A (cyclophilin A), and
glyceraldehyde-3-phosphate dehydrogenase (Gapdh)]. The
levels of mRNA were expressed as the ratio of the estimated
amount of the target gene relative to the TBP mRNA levels with
the use of the fluorescence threshold cycle values (Ct)
calculated for each sample, and the estimated efficiency of the
PCR for each product was expressed as the average of the
sample efficiency values obtained [24]. The primer sequences
are as follows: Scd1: forward 5’-
CTGACCTGAAAGCTGAGAAG-3’ and reverse 5’-
ACAGGCTGTGCAGGAAAGTT-3’; and TBP: forward 5’-
TGGGATTGTACCACAGCTCCA-3’ and reverse 5’-
CTCATGATGACTGCAGCAAAC C-3’.
Western blot analysis of liver Scd1 protein.  Proteins from
liver tissue were partially denatured in SDS sample buffer,
separated with 8% SDS-acrylamide gel, and electrotransferred
to Hybond-PVDF membranes (GE Healthcare UK Limited,
Buckinghamshire, UK). After blocking with 5% nonfat dry milk
in TBST buffer [20 mmol/L of Tris–HCl (pH 7.6), 137 mmol/L of
NaCl, and 0.25% of Tween-20], the membranes were probed
with rabbit polyclonal anti-Scd1 (Abnova, Taipei, Taiwan),
followed by incubation with HRP-conjugated anti-rabbit
polyclonal immunoglobulin G secondary antibody (GeneTex,
Inc., GTX26795, Irvine, CA, USA). Equal protein loading (40
µg) was confirmed by re-blotting of the membranes with a goat
polyclonal antibody against rabbit polyclonal anti-β-actin
(1:500) (GeneTex, Inc., GTX16039, Irvine, CA, USA). Binding
of the antibody was subsequently visualized with an enhanced
chemiluminescence reagent (GE Healthcare UK Limited,
Buckinghamshire, UK), and the band images were detected
and analyzed with the LabWorks Analysis Software (Ultra-
Violet Products Ltd, Cambridge, UK).
ELISA analysis of liver scd1 protein.  Liver scd1 levels
were measured in duplicate using a quantitative enzyme-linked
immunoassay specific for rat according to the manufacturer’s
instructions (USCN Life Science Inc, Houston, TX, USA);
sensitivity: the minimum detectable dose of this kit is less than
1.38 pg/µL. All samples were tested blind to the experimental
groups. Results are normalized by µg of liver protein in the
extract.
Statistical Analysis.  Quantitative data were expressed as
mean ± SE. The data were also adjusted for body length
whenever applicable. Pairwise mean differences were
evaluated with the nonparametric Mann–Whitney test because
most of the variables were ratios and not normally distributed,
SCD1 and Fatty Liver
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and/or nonhomogeneous variances between the groups were
evident. For the comparison of more than two groups, we used
the Kruskall–Wallis test. To test the differences in steatosis
gradation (as a categorical response variable), we used
ANCOVA with ordinal multinomial distribution, with probit as a
link function and strain and diet as categorical factors adjusting
for the indicated variables.
A value of p < 0.05 was considered to be statistically
significant. We used the Statistica software package (StatSoft,
Tulsa, OK, USA) for all the analyses.
Experimental Results
HFD-fed rats developed severe hepatic microvesicular and
macrovesicular steatosis independently of the rat strain and the
disease model (Figure 1, left panel). This finding was confirmed
by biochemical analysis of the hepatic triglyceride content in
rats of both experimental models (Figure 1, right panel).
In the model of HFD-induced NAFLD without IR, HFD-fed
rats showed significant changes in body weight and visceral fat
deposition when compared with their controls (Figure 1, right
panel). Nevertheless, the plasma glucose in the HFD group
was not significantly different from that in the CD group (199±6
and 186±7 mg/dL, respectively). Similarly, the plasma insulin
levels and HOMA index, despite being lower in the CD group
(96±35 and 45±19 µU/L, respectively), were not statistically
different when compared with those observed in the HFD group
(187±30 and 96±16 µU/L, respectively). Thus, despite the trend
(p<0.06), HOMA-IR was not significantly different among rats
consuming either CD or HFD (Figure 1, right panel).
On the other hand, in the genetic model of MS, exposure to
HFD was associated with significant changes in body weight
and visceral fat deposition in both the SHR and the control
WKY strains (Figure 1). Nevertheless, only the SHR strains
were insulin-resistant, as shown by significant differences in
the HOMA index between strains (Figure 1, right panel).
The analysis of the liver mRNA expression of Scd1 showed
substantial differences between rats fed with HFD vs. controls
(Figure 2). In both experimental models, Scd1 mRNA
significantly decreased when the rats were fed HFD.
Nevertheless, changes in the hepatic Scd1 mRNA abundance
were also observed in the insulin-resistant SHR vs. WKY rats
even under CD.
To further explore whether changes in liver Scd1 mRNA
were associated with changes in liver protein expression, we
measured the liver abundance of Scd1 protein by Western blot
and observed that HFD was associated with a decreased level
of Scd1 transcript and loss of liver Scd1 protein dimerization
Figure 1.  Left Panel: Liver histology of a representative animal from each experimental group.  Hematoxylin and eosin
staining of liver sections of a representative rat from each experimental group at the end of the experiment. The liver of rats fed with
standard chow diet (CD) shows normal histology and absence of fat accumulation. The liver of rats fed with high fat diet (HFD)
shows severe panlobular microvesicular and macrovesicular steatosis. Original magnification: 400×.
Right panel: Phenotypic characteristics and biometric variables in the experimental models according to diet.
Bar plots of steatosis score, liver triglyceride content, visceral fat weight (normalized by animal length), HOMA-IR, serum leptin
levels (ng/mL), and body weight in Sprague Dawley (SD) rats that developed HFD-induced NAFLD without IR (upper panel) and in
the HDF-induced NAFLD in the genetic model of MS in the SHR and its normotensive, insulin-sensitive control WKY strain (lower
panel).
HFD-induced NAFLD: Each bar represents the mean ± SE values of SD rats randomly divided into two experimental groups (CD:
n=10; HFD: n=15).
HFD-induced NAFLD in the genetic model of MS: Each bar represents the mean ± SE values of SHR (n=13) and WKY (n=14)
randomly divided into two experimental groups (standard chow diet CD:SHR, n= 6 and WKY, n=7; high fat diet HFD: SHR, n=7 and
WKY, n=7).
doi: 10.1371/journal.pone.0076912.g001
SCD1 and Fatty Liver
PLOS ONE | www.plosone.org 4 September 2013 | Volume 8 | Issue 9 | e76912
(Figure 3). In fact, the analysis of liver Scd1 protein expression
showed a particular pattern in the HFD groups, characterized
by the presence of a high level of protein expression of a
monomeric band (32.2–36.6 KDa, p<0.003) and a decreased
level of a dimeric band (61.0–66.1 KDa, p<0.02) regardless of
the rat strain (Figure 3). The monomer/dimer ratio was
significantly (p<0.0002) higher in the HFD rats (HFD-SHR: 1.9
vs. CD-SHR: 0.55 and HFD-WKY: 2.1 vs. CD-WKY: 0.9). SHR
showed decreased total Scd1 protein levels when compared
with WKY rats (p<0.02).
Liver tissue levels of scd1 protein were also measured by
ELISA and we observed that HFD was significantly associated
with decreased protein levels in both experimental rat models
(Figure 3, right panels).
Interventional experiment
Because previous data have shown that hepatic SCD1 gene
expression is regulated by peroxisome proliferators (PPARs)
and that clofibrate induces liver SCD1 mRNA levels up to 22-
fold in 30 h [25], we decided to explore the effect of this PPAR
alpha agonist on hepatic Scd1 gene and protein expression.
Previous results have shown that Scd1 mRNA and protein
exhibited similar behavior in both experimental models; hence,
we chose one of them, as explained in the Methods section, to
avoid the unnecessary use of animals.
Interestingly, clofibrate was found to not only improve fatty
liver but also modify the effects of HFD on Scd1 gene and
protein expression (Figure 4) because we observed that liver
Scd1 mRNA and protein expression were significantly induced
by clofibrate when compared with that in CD-fed animals
(Figure 4).
Discussion
In this study, we observed that diet-induced NAFLD is
associated with a dramatic decrease in Scd1-mRNA
abundance, which was not affected by the status of peripheral
IR. Indeed, HFD produced a significant downregulation of liver
Scd1 mRNA in both experimental models; this was also
associated with changes in Scd1 protein expression, which
behaved in a similar fashion. Thus, whereas the modulation of
Scd1 mRNA induction and protein content is part of a robust
system that is highly sensitive to dietary and hormonal factors,
at least in the liver tissue, it is not critically modified by the
status of IR. Moreover, we observed that HFD-induced NAFLD
was associated with significant changes in Scd1 protein
dimerization, which was reverted by the use of clofibrate, a
powerful PPAR alpha agonist that was also able to improve fat
accumulation in hepatocytes.
Previous evidence showed that the level of PUFAs strongly
influence the abundance of Scd1-mRNA in the liver. For
instance, Landschulz et al. showed that the levels of primarily
polyunsaturated (18:2 and 18:3) fat markedly suppress the
expression of the hepatic SCD1 message [26]; a similar
observation was replicated recently by McNamara et al [27].
Furthermore, it is worth mentioning an additional comment
regarding the putative constitutive differences in liver Scd1
mRNA expression between SHR and WYT. Indeed, there is
scarce information about this issue; nevertheless a previous
work reported that a SHR/NIH corpulent rat substrain (SHR/
NDcp), which was obtained by crossing SHR/NIH corpulent rat
with SHR, shows 5.5 times higher scd1 gene expression than
that of WKY but also showed a tendency of the original SHR
Figure 2.  Analysis of liver Scd1 mRNA abundance by quantitative real-time PCR in both experimental groups.  Left panel:
Each bar represents the mean ± SE values of Sprague Dawley (SD) rats randomly divided into two experimental groups (standard
chow diet CD: n=10; high fat diet HFD: n=15).
Right panel: Each bar represents the mean ± SE values of SHR (n=13) and WKY (n=14) divided into two experimental groups
(CD:SHR, n= 6 and WKY, n=7; HFD: SHR, n=7 and WKY, n=7). The statistical significance of SHR vs. WKY indicates the
comparison between strains independent of diet by two-way ANOVA.
In each sample, the Scd1 expression was normalized by the expression of Tbp (TATA box binding protein).
doi: 10.1371/journal.pone.0076912.g002
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strain to have decreased levels of Scd1 expression in
comparison with WKY rats [28].
To our knowledge, an association between changes in liver
Scd1 protein expression and changes in the pattern of protein
dimerization in relation with NAFLD has not been previously
reported.
Protein oligomerization and dimerization affects protein
function, cross-talk with other proteins, assembly with protein
complexes involved in gene expression, protein structure, and
protein relationship with cellular organelles [29]. Accordingly,
Zhang et al. showed in vitro that the dimerization and
oligomerization of SCD proteins play an important role in
regulating the half-life of SCD enzymes [21]. In addition, they
showed that although SCD oligomers are not stable, they do
not affect protein expression because degradation products
increase proportionally with the SCD protein levels [21]. This
novel mechanism of SCD protein regulation might significantly
affect the enzyme activity and function. These observations
makes a lack of specificity of the antibody we used although
possible, unlikely. Considering the leading role of hepatic lipid
metabolism in the pathogenesis of MS [30–32], it is tempting to
speculate that changes in the SCD1 expression in the liver
might significantly alter the hepatic lipid metabolism
aggravating the systemic metabolic derangement observed in
patients with MS.
In fact, despite the heterogeneous published evidence about
the impact of the hepatic SCD1 transcriptional activity on liver
and systemic lipid metabolism, it is evident that decreased
SCD1 activity is associated with lipoapoptosis [33], lipotoxicity
[6], and inflammation [8,33,34].
Functional association analysis with the use of the
bioinformatic resource GenMANIA [35] depicts the SCD1
genetic interactions, related pathways, and protein co-
expression, co-localization, and domain similarity (Figure 5).
Particularly, the analysis shows shared molecular pathways
between PPAR alpha and gamma and SCD1, including
pathways related to sequestering triglycerides (p< 0.04), as
well as negative regulation of lipid (p<0.05) and cholesterol
storage (p<0.045). More interestingly, the common molecular
pathways among PPAR alpha, PPAR gamma, and SCD1 also
include negative regulation of macrophage-derived foam cell
differentiation (p <0.045), an observation that illustrates the
involvement of the downregulation of hepatic SCD1
transcription in the worsening of the fatty liver phenotype [6]. A
Figure 3.  Analysis of liver Scd1 protein expression by Western blot and ELISA.  Upper left panel: Representative analysis of
liver Scd1 protein levels in each experimental model (SHR or WKY) with beta-actin as loading control. Upper right panel:
Densitometric quantification of liver SCD1 monomer/dimer ratio protein levels. Values are means ± SE for 13 animals in the SHR
group and 14 in the WKY group according to diet, as explained in the legends for Figures 1 and 2. Lower left and right panels:
Densitometric quantification of the liver Scd1 monomeric and dimeric band, respectively, in each experimental group according to
diet.
Liver scd1 protein expression measured by ELISA.
Upper right panel: HFD-induced NAFLD: Each bar represents the mean ± SE values of SD rats randomly divided into two
experimental groups (CD: n=10; HFD: n=15).
Lower right panel: Each bar represents the mean ± SE values of SHR and WKY divided into two experimental groups (CD:SHR, n=
6 and WKY, n=7; HFD: SHR, n=7 and WKY, n=7). Results are expressed pg/µl proteins.
doi: 10.1371/journal.pone.0076912.g003
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more detailed analysis and modeling of the biological networks
focused on SCD1 is shown in Figure 6. The additional
metanodes containing genes annotated under NR1H3 or
retinoid X receptor (RXR) (green nodes in circle), and
metanodes around HNF4a, INSIG1, and PTGS1 are
noteworthy.
Finally, we observed that interventional pharmacologic
approaches, such as improving NAFLD by clofibrate, not only
reverted the liver phenotype but also significantly affected the
hepatic Scd1 transcriptional activity and protein dimerization.
Thus, modulation of the hepatic SCD1 expression in NAFLD
might directly affect the global lipid metabolism. Further
investigations on humans must be carried out to precisely
define the role of hepatic SCD1 protein dimerization on
enzymatic activity and systemic lipid metabolism.
Figure 4.  Interventional experiment: Evaluation of the effect of clofibrate, an agonist of PPAR alpha, on hepatic Scd1
mRNA, protein expression and liver histology.  Each bar represents the mean ± SE values of Sprague Dawley (SD) rats fed with
standard chow diet CD (n=6), high fat diet HFD (n=5), and HFD plus clofibrate (n=5).
In each sample, the gene expression was normalized to the expression of Tbp (TATA box binding protein). The arrow shows the
characteristic hypertrophy of hepatocytes associated with PPAR alpha induction.
The liver histology of a representative animal from each experimental group shows the hematoxylin-and-eosin staining of liver
sections at the end of the experiment. Original magnification: 400×.
doi: 10.1371/journal.pone.0076912.g004
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Figure 5.  Results of functional association analysis by the bioinformatics resource GenMANIA (available at http://
www.genemania.org/, Toronto, Canada).  SCD (SCD1): stearoyl-CoA desaturase (delta-9-desaturase); CYB5A: cytochrome b5
type A (microsomal); CYP51A1: cytochrome P450, family 51, subfamily A, polypeptide 1, HMGCS1 3-hydroxy-3-methylglutaryl-CoA
synthase 1 (soluble); ELOVL5: ELOVL fatty acid elongase 5; SCD5: stearoyl-CoA desaturase 5; FADS6: fatty acid desaturase
domain family, member 6; ELOVL2: ELOVL fatty acid elongase 2; FADS1: fatty acid desaturase 1; ELOVL6: ELOVL fatty acid
elongase 6; DHCR7: 7-dehydrocholesterol reductase; SQLE: squalene epoxidase; PPARG: peroxisome proliferator-activated
receptor gamma; DEGS2: degenerative spermatocyte homolog 2, lipid desaturase; RXRB: retinoid X receptor, beta; RARA: retinoic
acid receptor, alpha; TF: transferring; PPARA: peroxisome proliferator-activated receptor alpha; DEGS1: degenerative
spermatocyte homolog 1, lipid desaturase; CYB561: cytochrome b-561; PHF20: PHD finger protein 20.
doi: 10.1371/journal.pone.0076912.g005
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Figure 6.  Analysis of interaction pathways (http://visant.bu.edu/) of SCD1; the metagraph structure allows the visualization
of bionetworks constructed by integrative data-mining features, which permits a large number of functional associations
for 103 different species.  Direct SCD1-related nodes are shown in red. A few nodes are labeled for the sake of simplicity. The
gene labels are official names.
doi: 10.1371/journal.pone.0076912.g006
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